---
title: "Kymera Therapeutics, Inc. (KYMR.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/KYMR.US.md"
symbol: "KYMR.US"
name: "Kymera Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-03-13T10:05:38.871Z"
locales:
  - [en](https://longbridge.com/en/quote/KYMR.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KYMR.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KYMR.US.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/KYMR.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/KYMR.US.md)


# Kymera Therapeutics, Inc. (KYMR.US)

## Company Overview

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.kymeratx.com](https://www.kymeratx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-13T04:30:16.000Z

**Overall: D (0.66)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 209 / 406 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -16.70% |  |
| Net Profit YoY | -39.08% |  |
| P/B Ratio | 3.87 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6118549592.50 |  |
| Revenue | 39211000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -25.78% | E |
| Profit Margin | -794.04% | E |
| Gross Margin | -707.34% | E |
| Revenue YoY | -16.70% | E |
| Net Profit YoY | -39.08% | D |
| Total Assets YoY | 78.20% | A |
| Net Assets YoY | 89.04% | A |
| Cash Flow Margin | -12.59% | D |
| OCF YoY | -16.70% | E |
| Turnover | 0.03 | E |
| Gearing Ratio | 9.36% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Kymera Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-16.70%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-39.08%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.87",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "6118549592.50",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "39211000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-25.78%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-794.04%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-707.34%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-16.70%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-39.08%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "78.20%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "89.04%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-12.59%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-16.70%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.03",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "9.36%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -19.65 | 498/406 | - | - | - |
| PB | 3.87 | 275/406 | 5.93 | 4.01 | 2.66 |
| PS (TTM) | 156.04 | 266/406 | 135.60 | 73.88 | 47.28 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Stoke Therapeutics (STOK.US) | A | A | B | A | B | A |
| 03 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 04 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-03T05:00:00.000Z

Total Analysts: **23**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 17 | 74% |
| Overweight | 5 | 22% |
| Hold | 1 | 4% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 77.50 |
| Highest Target | 140.00 |
| Lowest Target | 90.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/KYMR.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/KYMR.US/norm.md)
- [Related News](https://longbridge.com/en/quote/KYMR.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/KYMR.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**